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Increased levels of myeloid cells, especially myeloid-derived suppressor cells (MDSCs), 
have been reported to correlate with bad prognosis and reduced survival in cancer 
patients. However, limited data are available on their conclusive phenotypes and their 
correlation with clinical settings. The aim of this study was to investigate levels and 
phenotype of myeloid cells in peripheral blood and tumor microenvironment (TME) of 
colorectal cancer (CRC) patients, compared to blood from healthy donors (HDs) and 
paired, adjacent non-tumor colon tissue. Flow cytometric analysis was performed to 
examine the expression of different myeloid markers in fresh peripheral blood samples 
from CRC patients and HDs, and tissue-infiltrating immune cells from CRC patients. 
We found significantly higher levels of cells expressing myeloid markers and lacking 
the expression of major histocompatibility complex class II molecule HLA-DR in blood 
and tumor of CRC patients. Further analysis revealed that these cells were granulocytic 
and expressed Arginase 1 indicative of their suppressive phenotype. These expanded 
cells could be neutrophils or granulocytic MDSCs, and we refer to them as granulocytic 
myeloid cells (GMCs) due to the phenotypical and functional overlap between these cell 
subsets. Interestingly, the expansion of peripheral GMCs correlated with higher stage 
and histological grade of cancer, thereby suggesting their role in cancer progression. 
Furthermore, an increase in CD33+CD11b+HLA-DR−CD14−CD15− immature myeloid 
cells was also observed in CRC tumor tissue. Our work shows that GMCs are expanded 
in circulation and TME of CRC patients, which provides further insights for developing 
immunotherapeutic approaches targeting these cell subsets to enhance antitumor 
immune and clinical responses.
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inTrODUcTiOn
Evasion of immune response has been proposed as an emerging hallmark of cancer. Remarkable 
increase of cancers in immune-compromised patients provided further insights into the relation-
ship between immune suppression and increased susceptibility to cancers (1, 2). Therefore, studies 
focusing on mechanisms involving host immune suppression have attracted great interest in recent 
years. Myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) have been identified 
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as key mediators in the negative regulation of immune responses 
in tumor microenvironment (TME). Several studies showed that 
elevated levels of immunosuppressive cells in periphery, tumor-
draining lymph node, and TME correlates with worse prognosis 
and tumor progression in various cancers (3).
Myeloid-derived suppressor cells are a heterogeneous popu-
lation of myeloid origin, which exhibit a potent immunosuppres-
sive activity against T-cell responses (4). Cells of myeloid origin 
were first described in cancer patients as natural suppressor 
cells (5). MDSCs are expanded in different pathophysiological 
conditions including cancers (6). The terminal differentiation 
of immature myeloid cells (IMCs) is halted at varying stages of 
maturation and differentiation giving rise to a morphological 
mixture of granulocytic and monocytic cells, which are immu-
nosuppressive in nature (7).
Myeloid-derived suppressor cells are commonly identi-
fied as cells expressing common myeloid markers CD33 and 
CD11b, but lack the expression of markers for mature myeloid 
and lymphoid cells and the major histocompatibility complex 
(MHC) class II molecule HLA-DR (7). Human MDSCs are 
broadly classified into monocytic (M) and granulocytic (G) or 
polymorphonuclear (PMN) subset based on the expression of 
CD14 and CD15 markers (8). Monocytic MDSCs (M-MDSCs) 
are mostly CD33+CD11b+CD14+HLA-DR−/low, whereas granu-
locytic MDSCs (G-MDSCs) are CD33+CD11b+HLA-DR−/low 
CD14−CD15+ (9, 10). A third population of MDSCs has also 
been described as immature or early stage MDSCs, lacking CD14, 
CD15, and HLA-DR (11). Surface markers of G-MDSC includ-
ing CD11b, CD33, and CD15 are also well-established markers 
for mature neutrophil granulocytes. Neutrophils and G-MDSC 
share phenotypical properties and functional characteristics. It 
is challenging to distinguish between neutrophils and G-MDSC, 
and currently, there is no accepted consensus on exclusive mark-
ers to differentiate them. Pillay et  al., however, suggested that 
G-MDSCs could be a phenotypic subset of neutrophils with 
functional heterogeneity (12).
Several studies have shown that levels of neutrophils and 
MDSCs are increased in peripheral blood and TME in various 
cancers and exhibit tumor-specific immunosuppression and 
tumor-promoting effects (13–15). However, neutrophils have 
been shown to exhibit a dual role in tumor development by 
either promoting the growth, invasion, and metastasis of tumor 
or by exerting tumoricidal activity through secretion of antitu-
moral factors or by stimulating T-cell responses and antitumor 
immunity (16, 17). Elevated neutrophil to lymphocyte ratio is 
frequently reported in cancer patients and is used as a predictive 
and prognostic factor in various human cancers (15). In relation 
to their immunosuppressive role, neutrophils and MDSCs utilize 
various mechanisms, which involve production of Arginase 1 
(ARG1), inducible nitric oxide synthase, and reactive oxygen spe-
cies (18, 19). These cells have also been shown to play important 
roles in promoting growth of various cancers including colorectal 
cancer (CRC) (20).
Colorectal cancer is the third most common cancer 
worldwide and is responsible for around 0.5 million deaths 
per year (21, 22). It is an inflammatory cancer, often closely 
related to inflammatory bowel disease, and inflammation is 
recognized as a key factor in the pathogenesis of both sporadic 
and hereditary CRC (23). The disruption of myelopoiesis and 
hemopoiesis are recognized as the key immune mechanisms 
involved in inflammation-related tumorigenesis, which result 
in the accumulation of MDSCs (24). Although higher levels of 
circulating or tumor-infiltrating MDSCs have been reported 
in CRC patients (25, 26), there is not enough information 
regarding the phenotypical characterization of these cells. 
Therefore, studies identifying and characterizing various sub-
types of MDSCs in CRC patients are warranted. In the present 
study, we compared levels of circulating myeloid cells between 
healthy donors (HDs) and CRC patients and investigated ARG1 
expression, indicative of their suppressive phenotype. We found 
significant increase in the levels of different subsets of myeloid 
cells in peripheral blood of CRC patients compared with HDs. 
We also found that higher levels of myeloid cells of granulocytic 
and immature phenotypes accumulated in tumor tissue (TT) 
compared with adjacent non-tumor colon tissue. Our findings 
identify the expansion of granulocytic myeloid cells (GMCs) 
in circulation and TME of CRC patients and provide insights 
for immunotherapeutic strategies targeting these cells in CRC 
patients.
MaTerials anD MeThODs
Patients and healthy Donors
Peripheral blood samples were collected in heparinized tubes 
(200 IU) from patients with CRC (n = 21) at Tawam Hospital, Al 
Ain, UAE and Al Noor Hospital, Abu Dhabi, UAE. Additionally, 
tumor tissues (TT) and paired, adjacent non-tumor colon tis-
sues (NT) were collected from patients who underwent surgery 
(n  =  9). Peripheral blood samples were also collected from 
HDs (n = 21) as controls. None of the patients included in this 
study received any treatment prior to surgery. Ethical approval 
was obtained from Al Ain Medical District Human Research 
Ethics Committee and written consent forms were signed by 
all patients and donors prior to collection of samples. Table 1 
shows clinical and pathological characteristics of all participat-
ing individuals.
enzyme Disaggregation of Tumor and 
normal Tissues for cell isolation
Fresh colorectal TT and NT were collected in cold RPMI-1640 
media. Enzyme disaggregation (ED) of tissue was performed 
on a rollover mixer at 37°C for 60 min. Briefly, tissues were first 
washed with phosphate-buffered saline (PBS) and then mechani-
cally cut into small pieces (around 2–4  mm) using a surgical 
scalpel. Samples were then suspended into RPMI-1640 with 1% 
penicillin/streptomycin and enzyme cocktail, consisting of 1 mg/
ml collagenase, 100 μg/ml hyaluronidase type V, and 30 IU/ml 
of deoxyribonuclease I (all from Sigma-Aldrich, UK). The cell 
suspension was then passed through a 100 μm BD Falcon cell 
strainer (BD Biosciences, Oxford, UK) to remove debris and 
aggregates. Cells were then washed with RPMI-1640 and resus-
pended in RPMI-1640 enriched with 10% FCS and 1% penicillin/
streptomycin.
TaBle 1 | characteristic features of study populations.
hD crc
Number 21 21 (9)b
Age (median) 30 (19–51)a 46 (32–74)a






Tumor size (cm) 4.2 (0.2–10)a





HD, healthy donor; CRC, colorectal cancer.
aData shown represent median (range).
bSamples taken from patients for investigating tissue-infiltrating immune cells.
3
Toor et al. Myeloid Cells in CRC Patients
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 560
staining of Whole Blood and  
Tissue-infiltrating immune cells  
for Flow cytometric analyses
Two hundred microliters of blood from each sample was used 
for whole blood staining for different MDSC markers; 100 μl 
was used as non-stained control and 100  μl was stained for 
each sample. Mouse anti-human CD33-APC (Clone WM53), 
mouse anti-human CD11b-APC-Cy7 (Clone ICRF44), mouse 
anti-human HLA-DR-PE (Clone G46-6), mouse anti-human 
CD14-PerCP-Cy5.5 (Clone M5E2), and mouse anti-human 
CD15-PE-Cy7 (Clone HI98) antibodies were added to the 
stained sample. All antibodies were purchased from BD 
Biosciences. Tubes were incubated at 4°C for 25  min. RBC 
lysis buffer (BD FACS lysing solution) was then added to each 
tube and incubated in dark for 5 min. After washing the sam-
ples twice with PBS, cells were fixed and permeabilized using 
Fixation/Permeabilization Buffer (eBioscience, San Diego, CA, 
USA) and incubated at 4°C for 45 min after thorough vortex-
ing. Samples were then washed twice with permeabilization 
wash buffer (eBioscience) and stained with sheep anti-human/
mouse ARG1-FITC antibody (R&D Systems, Minneapolis, MN, 
USA) for intracellular staining by incubating at 4°C for 25 min, 
followed by two washes with wash buffer (eBioscience). The 
cell pellet was resuspended in 300 μl of flow cytometry stain-
ing buffer (eBioscience) to analyze on BD FACS Canto II flow 
cytometer (BD Bioscience, USA).
For staining immune cells extracted by ED, cells were first 
blocked for Fc receptor using FcR Blocker (Miltenyi Biotec, 
Bergisch Gladbach, Germany). 7AAD viability dye (eBiosci-
ence) was added, followed by staining with mouse anti-human 
CD11b-APC-Cy7 (BD Biosciences), mouse anti-human CD33-
FITC (Clone P67.6, BioLegend, San Diego, CA, USA), mouse 
anti-human HLA-DR-PE (BD Biosciences), CD14-PE-Cy7 
(Clone 61D3, eBioscience), and mouse anti-human CD15-APC 
(Clone HI98, BioLegend). After incubation at 4°C, samples were 
washed twice with PBS and the pellet was resuspended in 300 μl 
flow cytometry staining buffer (eBioscience) for analyzing on 
BD FACS Canto II flow cytometer. Flow cytometric data were 
analyzed on BD FACSuite software (BD Biosciences).
statistical analyses
Statistical analyses were performed using GraphPad Prism 
5.0 software (GraphPad Software, USA). Paired/Wilcoxon 
matched-pairs signed rank test or unpaired/Mann–Whitney 
tests were used to examine the differences within groups or 
between groups, respectively. A p value of ≤0.05 was considered 
statistically significant. The data are presented as means ± SEM. 
Levels of cells were measured as relative percentages or calcu-
lated percentages from parent population(s). For statistical 
analyses, staining of 20 peripheral blood samples from CRC 
patients was used.
resUlTs
cD33+cD11b+hla-Dr−/low Myeloid cells 
are expanded in Peripheral Blood of crc 
Patients, compared with healthy Donors
We investigated levels and nature of myeloid cells in circulation 
and TME of CRC patients using flow cytometric analysis of dif-
ferent markers. Flow cytometric plots of the gating strategy used 
to identify myeloid cells are shown in Figure 1A. Fluorescence 
minus one (FMO) controls were used for all markers to iden-
tify positive populations (Figures S1A–E in Supplementary 
Material). Scatter plots of the means of calculated percentages 
±SEM of each myeloid subpopulation are shown in Figure 1B. 
The frequency of each population was calculated out of the par-
ent population. The relative percentages of each population were 
multiplied by relative percentage of its parent population and 
the resulting number was presented as calculated percentage. 
We found that CRC patients had significantly higher levels of 
CD33+ cells compared with HDs (CRC: 85.3 ±  2.0% vs. HD: 
78 ± 2.9%; Figure 1B). Further analysis showed a similar trend 
in the levels of CD33+CD11b+ cells; CRC patients showed sig-
nificantly higher levels of CD33+CD11b+ subsets compared with 
HDs (CRC: 81.9 ± 2.1% vs. HD: 74.6 ± 2.6%; Figure 1B). MDSCs 
are known to lack the expression of HLA-DR (27, 28); therefore, 
we investigated expression of HLA-DR within CD33+CD11b+ 
subsets. Levels of circulating CD33+CD11b+HLA-DR−/low sub-
sets in CRC patients were also significantly higher compared 
with HDs as shown in Figure 1B (CRC: 78.2 ± 2.7% and HD: 
70.9 ± 2.4%).
The expanded Myeloid cells in Peripheral 
Blood of crc Patients are granulocytic
To find out if the expanded circulating myeloid cells in CRC 
patients are granulocytic or monocytic, we analyzed expression of 
CD15 and CD14 within the CD33+CD11b+HLA-DR−/low subsets. 
CRC patients showed significantly higher levels of circulating 
CD33+CD11b+HLA-DR−/lowCD15+ cells compared with HD 
(CRC: 75.8 ±  2.8%, HD: 67.1 ±  2.7%; Figure  1B). These cells 
could be neutrophil granulocytes or G-MDSCs (12); however, 
FigUre 1 | gating strategy of myeloid cells and comparisons of levels of different subsets of circulating myeloid cells between hDs and crc 
patients. Representative flow cytometric plots showing the gating strategy used to identify myeloid cells in peripheral blood of HDs and CRC patients (a). CD33+ 
cells were gated first from all cells, followed by gating CD11b+ cells and HLA-DR−/low cells from parent populations. MMCs were then identified as CD14+ cells, while 
GMCs were identified based on the expression of CD15. Fresh whole blood from 21 HDs and 20 CRC patients was stained for these markers. (B) Shows scatter 
plots of the means of calculated percentages ± SEM of each myeloid subpopulation including CD33+ cells, CD33+CD11b+ cells, CD33+CD11b+HLA-DR−/low cells, 
CD33+CD11b+HLA-DR−/lowCD14+ cells, and CD33+CD11b+ HLA-DR−/lowCD15+ cells.
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due to lack of conclusive evidence on their suppressive ability, we 
referred to them as GMCs. We also investigated levels of CD14+ 
cells within the CD33+CD11b+HLA-DR−/low populations in the 
two study groups. There was no significant difference in levels 
of CD33+CD11b+HLA-DR−/lowCD14+ monocytic myeloid cells 
(MMCs) in CRC patients compared to HDs (CRC: 2.4 ± 0.5%; 
HD: 3.2 ± 0.5%; Figure 1B). The overall levels of MMCs were sig-
nificantly lower than GMCs in the two study groups (p < 0.001) 
(Figure  1B). We also investigated the levels of IMCs subset, 
which lack CD14 and CD15 expression, but did not find any 
difference in level of these cells between the two study groups 
(data not shown).
arg1 expression in Myeloid cell subsets
Myeloid-derived suppressor cells express high levels of ARG1, 
which assists in their characteristic attribute of T-cell suppres-
sion (6). We examined expression of ARG1 by both MMCs 
and GMCs. Figures 2A,B show flow cytometric plots of ARG1 
expression by CD33+CD11b+HLA-DR−/lowCD14+ MMCs and 
CD33+CD11b+HLA-DR−/lowCD15+ GMCs in a HD and CRC 
patient, respectively. Flow cytometric plots for FMO for ARG1 
are shown in Figure S1F in Supplementary Material. Both subsets 
expressed different levels of ARG1 (Figure 2). Levels of ARG1-
expressing GMCs were significantly higher in peripheral blood of 
CRC patients than HDs (CRC: 63.1 ± 2.9% vs. HD: 45.3 ± 3.7%; 
Figure 2C). There was no significant difference in levels of ARG1-
expressing MMCs in the two study groups (CRC: 0.7 ± 0.2, HD: 
0.6 ± 0.2; Figure 2D). In line with our previous study in pancreatic 
cancer patients (29), GMCs expressed significantly higher levels 
of ARG1 than MMCs (Figures 2C,D).
Tumor-associated gMcs and iMcs are 
expanded in colorectal Tumor Tissue, 
compared with normal colon Tissue
A major focus of this study was to investigate the nature and 
levels of myeloid cells in TME. We examined levels of tumor-
infiltrating myeloid cells in CRC TTs and compared with NT 
from each patient (Figure  3A). Viable cells were first gated 
using 7AAD viability dye, followed by gating based on expres-
sion of myeloid cell markers. We found significant increase in 
levels of myeloid cells in TT compared with NT from nine CRC 
patients. There was an increase in CD33+, CD33+CD11b+, and 
CD33+CD11b+HLA-DR−/low subsets in TT compared with NT in 
CRC patients (Figure 3A).
When further investigated, if these myeloid cells are of 
monocytic or granulocytic nature, we found that, similar to 
the results obtained in peripheral blood, this expansion was 
in CD33+CD11b+HLA-DR−/lowCD15+ GMCs. There was a 
significant increase in the relative percentage of CD15+ GMCs 
in TT compared with NT (NT: 11.2 ±  4.0 vs. TT: 27.6 ±  5.0; 
Figure  3B). This difference was further confirmed when the 
numbers were calculated based on the percentage of parent 
population; there was a significant increase in the calculated 
percentages of CD15+ cells within CD33+CD11b+HLA-DR−/low  
populations in TT compared with adjacent NT (NT: 0.03% 
vs. TT: 0.9%; Figure  3C). In contrast, there was a significant 
FigUre 2 | arginase 1 expression by MMcs and gMcs in peripheral blood of hDs and crc patients. Fresh blood from HD (n = 21) and CRC patients 
(n = 20) was stained for different MDSC markers to identify MMCs and GMCs cells, followed by intracellular staining for the expression of ARG1. Representative flow 
cytometric plots showing expression of ARG1 by CD33+CD11b+HLA-DR−/lowCD14+ MMCs and CD33+CD11b+HLA-DR−/lowCD15+ GMCs cells in a HD (a) and a CRC 
patient (B). Scatter plots comparing calculated percentages ± SEM of ARG1 level in CD33+CD11b+HLA-DR−/lowCD15+ (c) and CD33+CD11b+HLA-DR−/lowCD14+ (D) 
subsets.
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reduction in relative percentage, but not calculated percentage, of 
CD33+CD11b+HLA-DR−/lowCD14+ MMCs in TT compared with 
NT (NT: 4.5 ± 1.4 vs. TT: 2.0 ± 0.7; Figures 3B,C). Furthermore, 
similar to peripheral blood, levels of GMCs were significantly 
higher than MMCs in both NTs and TTs (Figures 3B,C). There 
was also a significant increase in calculated percentage of 
CD33+CD11b+HLA-DR−CD14−CD15− (IMCs) in TT compared 
with NT (Figure 3D).
We investigated expression of ARG1 by monocytic and granu-
locytic populations in cells isolated from NT and TT of three CRC 
patients. Both tumor-infiltrating CD33+CD11b+HLA-DR−/low 
CD14+ and CD33+CD11b+HLA-DR−/lowCD15+ cells expressed 
ARG1. Representative plots showing expression of ARG1 in these 
cell subsets are shown in Figures 3E,F. However, sufficient data 
were not collected for statistical analysis due to limited number 
of samples.
circulating arg1-expressing gMcs are 
expanded in crc Patients with regional/
Distant Metastases and in Patients with 
Poorly Differentiated Tumors
Next, we investigated if the expansion of GMCs in CRC patients 
could potentially correlate with tumor stage or histological grade. 
In peripheral blood analysis, patients were divided into two 
groups according to TNM stage; patients with localized disease 
(stages I and II; n = 9) and patients with regional lymph node or 
distant metastases (stages III and IV; n = 11). We found signifi-
cantly higher levels of circulating GMCs in patients with regional/
distant metastases compared with HDs, and these cells expressed 
higher levels of ARG1 (Figures 4A,B). Although there was no dif-
ference in GMCs levels between HDs and patients with localized 
CRC (Figure 4A), GMCs in these patients expressed significantly 
FigUre 3 | Myeloid cells and arginase 1 expression in tissue-infiltrating immune cells. (a) Representative flow cytometric plots showing levels of different 
subsets of myeloid cells in normal tissue (NT) and tumor tissue (TT) of nine CRC patients. Doublets were excluded and live cells were gated. The frequency of each 
population was calculated out of the parent population. Scatter plots showing mean of relative percentages ± SEM (B), and calculated percentages ± SEM, 
calculated by multiplying the relative percentages of each subpopulation with their respective parent populations, of CD33+CD11b+HLA-DR−/low CD14+ MMCs and 
CD33+CD11b+HLA-DR−/low CD15+ GMCs in NT and TT of CRC patients (c); inset showing the expansion of GMCs in TT compared with adjacent NT. (D) Means of 
calculated percentage ± SEM of CD33+CD11b+HLA-DR−CD14−CD15− IMCs in NT and TT. Representative flow cytometric plots show the expression of ARG1 by 
tumor-infiltrating CD33+CD11b+HLA-DR−/lowCD14+ MMCs (e) and CD33+CD11b+HLA-DR−/lowCD15+ GMCs (F) in tumor tissue of CRC patients.
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higher levels of ARG1 compared with HDs (Figure 4B). There 
were no differences in ARG1-expressing myeloid cells when com-
pared between patients with different tumor stages. Furthermore, 
there was no significant difference in MMCs levels between 
patients with different tumor stages and HDs (data not shown).
We also found significant differences in levels of circulating 
myeloid cells between HDs and CRC patients when categorized 
based on histological grade of differentiation of tumor cells 
(Figures 4C,D). Patients with histological grade I and II cancers 
had well to moderately defined tumor cells and are grouped as 
“low-grade tumors”; while grade III patients presented with 
poorly or undifferentiated tumor cells and are referred as “high-
grade tumors”. CRC patients with high-grade tumors (n = 4) had 
significantly higher levels of circulating CD33+, CD33+CD11b+, 
and CD33+CD11b+HLA-DR−/low cells compared with HDs 
(n =  21) and patients with low-grade tumors (n =  16). The 
expansion of CD33+CD11b+HLA-DR−/low cells was due to 
increase in the granulocytic CD15+ subset; high-grade CRC 
patients had significantly elevated levels of GMCs than HDs 
(high-grade: 86.0 ± 2.2 vs. HDs: 67.1 ± 2.7; Figure 4C) and 
FigUre 4 | comparisons of levels of circulating gMcs between hDs and different TnM stages and histological grades of colorectal cancer. Scatter 
plots comparing calculated percentages ± SEM of CD33+CD11b+HLA-DR−/lowCD15+ GMCs (a) and their ARG1 level (B) between HDs and different TNM stages of 
CRC patients. Scatter plots comparing calculated percentages ± SEM of CD33+CD11b+HLA-DR−/lowCD15+ GMCs (c) and their ARG1 level (D) between HDs and 
different histological grades of CRC patients.
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low-grade CRC patients (low-grade: 73.2 ±  3.2; Figure  4C). 
Furthermore, these cells expressed high levels of ARG1 (high-
grade 74.8 ±  3.1; HDs: 45.26 ±  3.7; low-grade: 60.1 ±  3.1; 
Figure  4D). There was no difference in expression levels of 
CD33+CD11b+HLA-DR−/lowCD15+ cells between patients 
with low-grade tumors and HDs (Figure 4C), but these cells 
expressed significantly higher levels of ARG1 in low-grade 
CRC patients compared with HDs (Figure 4D). There was no 
difference in the levels of MMCs and their ARG1 expression 
between the two patient subgroups and HDs (data not shown). 
For tumor-infiltrating immune cells, it was not possible to 
compare patients based on tumor stage or histological grade 
due to limited sample size.
DiscUssiOn
In recent years, several studies have reported expansion of 
regulatory myeloid cells including neutrophils and MDSCs in 
peripheral blood and TME of different human cancers (9, 12, 
15, 19). Human MDSCs consist of immature progenitor cells 
and mature cells of mononuclear or PMN phenotype. However, 
due to their heterogeneous nature, specific markers of human 
MDSCs are not well defined. It is also very difficult to discriminate 
between G-MDSCs and neutrophil granulocytes, which share 
phenotypical and functional characteristics. As a result, most of 
the studies have provided inconclusive evidence of their immu-
nophenotypical nature. Moreover, a role of tumor-infiltrating 
myeloid cells in cancer patients is not well defined, and very few 
studies have reported their levels in peripheral blood and TME 
from the same cancer patients. In this study, untreated CRC 
patients with different tumor stages and histological grades were 
examined for the parallel analysis of myeloid cell levels in circula-
tion and TME, and were compared with their levels in peripheral 
blood of HDs. As a control for their levels in TME, cells isolated 
from paired, adjacent non-tumor colon tissue were used from 
the same patients.
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We used freshly drawn whole blood for analysis because vari-
ous studies emphasized on the importance of sample handling and 
processing when monitoring levels of myeloid cells in circulation 
(10, 28, 30, 31). Florcken et  al. did not find any differences in 
the expression levels of MDSC when analyzed in whole blood or 
PBMCs (31). However, Mandruzzato et al. suggested to monitor 
MDSC levels in whole blood instead of Ficoll-purified mononu-
clear cells as some MDSC subsets might not be detected if only 
PBMCs were examined (30). Fresh blood is preferred to prevent 
possible loss of GMCs and attenuation of cell surface markers due 
to Ficoll gradient separation (10).
We found significantly higher levels of circulating 
CD33+CD11b+ HLA-DR− cells in CRC patients compared with 
HDs. This expansion is in accordance with previously reported 
findings (25, 26, 28). Additionally, we report that these expanded 
cells are granulocytic in nature. Studies on other cancers includ-
ing cutaneous melanoma also reported the accumulation of 
circulating granulocytic MDSC like cells in patients compared 
to HDs (10, 32). Zhang et al., however, reported the expansion 
of IMCs lacking CD14 and CD15 in CRC (26). Furthermore, in 
contrast to monocytic MDSCs, which are commonly reported 
within different cancers, less evidence is available on levels of 
granulocytic MDSCs in cancers (33). Thus, our findings provide 
a further insight into myeloid cells in CRC.
Previous studies have investigated the functional activity of 
neutrophils and MDSCs through their suppression of T cells 
in vitro and expression of ARG1. T-cell suppression by myeloid 
cells is well documented in different cancers, such as gastric 
cancer (34), prostate cancer (35), breast cancer (28), and CRC 
(26). l-arginine is required for the proliferation and function of 
T cells and ARG1 results in the depletion of l-arginine in the 
microenvironment, thereby limiting its availability for T cells, 
which reduces their expression of CD3ζ chain, inhibit T-cell pro-
liferation, and induce T-cell apoptosis (32, 36). It has previously 
been shown that production of ARG1 by mature myeloid cells in 
TME could inhibit antigen-specific T cell responses (37). Other 
studies have also demonstrated T-cell suppression by MDSCs 
through ARG1 (38). We found that the expanded circulating 
GMCs express ARG1 with higher mean fluorescence intensity 
(MFI) than MMCs (data not shown). Similar to peripheral blood, 
we found significant accumulation of tumor-infiltrating myeloid 
cells compared to adjacent NT, which were primarily granulocytic 
and expressed ARG1.
Circulating GMCs were significantly elevated in CRC patients 
with regional and distant metastases compared with HDs. 
However, there were no differences in GMCs levels between 
patients with different tumor stages. These results are in agree-
ment with previous studies in CRC and cutaneous melanoma, 
which have also shown higher levels of MDSCs in metastatic 
cancers compared with control group (10, 26). There are stud-
ies, however, which reported significant differences in levels of 
myeloid cells between HDs and patients with low stage cancers, 
and between patients with different cancer stages (25, 28); this 
discrepancy could be due to the number of patients and type of 
cancer investigated.
Previous studies have highlighted the immunosuppressive 
functions of neutrophils and myeloid cells, which would facilitate 
tumors to evade local immune response, and a role of GMCs 
in invasion and metastases is emerging from ongoing research 
(11, 12, 19). Tumor cells secrete several soluble factors such as 
Interleukin 6 and GM-CSF, which influence bone marrow and 
help in expansion of myeloid cells. These cells accumulate in TME 
and produce factors such as VEGF, matrix metallopeptidase 9 
(MMP9), and transforming growth factor beta (TGF-β), which 
support angiogenesis and tumor growth and eventually invasion 
and metastases of tumor cells (11, 15, 39). Thus, our results sug-
gest a role of immunosuppressive GMCs in cancer invasion and 
metastases.
Grading of tumors depends upon histological differentiation 
of tumor cells compared to normal cells, and it represents how 
quickly a tumor can grow and spread. Histological grade has 
been shown to be stage-independent prognostic variable in 
CRC patients; high-grade CRC patients with poorly or undif-
ferentiated cancer cells have worse disease prognosis compared 
to low-grade CRC patients with well or moderately differenti-
ated tumor cells (40, 41). Our work shows that in high-grade 
CRCs, GMCs may play important role in tumor-mediated 
immune suppression and suggest their involvement in tumor 
progression.
In conclusion, our study shows that GMCs and IMCs are 
expanded in CRC patients. Importantly, expansion of GMCs 
correlated with tumor stage and histological grades, thereby 
identifying these cells as key players among others in CRC 
patients. Better understanding of their characteristics should aid 
in therapeutic strategies to target immunosuppressive pathways 
employed by tumors.
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